Home › Compare › LGYSF vs ABBV
LGYSF yields 2087.68% · ABBV yields 3.06%● Live data
📍 LGYSF pulled ahead of the other in Year 1
Combined, LGYSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LGYSF + ABBV for your $10,000?
Ling Yue Services Group Limited operates as a property management company in the People's Republic of China. The company offers a range of property management services, such as security services, cleaning and greening services, and repair and maintenance services to property owners, residents, and property developers, as well as tenants in non-residential properties. It manages a diverse portfolio of properties, including residential properties, commercial properties, and public and other properties. The company also provides value-added services to non-property owners, including preliminary planning and design consultancy, sales office management, pre-delivery, repair and maintenance, property transaction assistance, and security support services; and community value-added services primarily to property owners and residents comprising community space management, decoration and turnkey furnishing, convenient living, and community retail services. As of December 31, 2021, it had been contracted to manage 183 properties with an aggregate contracted GFA of approximately 20.8 million square meters under its management. The company was founded in 2002 and is headquartered in Chengdu, the People's Republic of China.
Full LGYSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.